Iovance expects update on melanoma program later this year
The company said in today's earnings release, "The dosing of the first patient with lifileucel in Europe for the treatment of metastatic melanoma marked an important milestone for Iovance and our global development plans as we continue our mission to develop TIL therapy as a treatment option for cancer patients. In line with expansion of the TIL platform, we are initiating investigation of TIL therapy in several new indications with high unmet need, as part of our collaboration with MD Anderson. We continue to advance our four company-sponsored trials and intend to provide an update regarding our melanoma program later this year." It added that enrollment in its global Phase 2 metastatic melanoma study, C-144-01, continues.